This second part of the trial enrolled 126 patients with NSCLC harboring KRAS G12C mutation, who had progressed after anti-PD-1/PD-L1 molecules and platinum-based chemotherapy alone or combined. This evidence concerns the gene KRAS and non-small cell lung carcinoma.